Zobrazeno 1 - 10
of 241
pro vyhledávání: '"Guru Sonpavde"'
Autor:
Syed A. Hussain, Catherine Curran, Giuseppe Di Lorenzo, Ruby Gupta, Pasquale Verolino, Moshe Chaim Ornstein, Petros Grivas, Archana Agarwal, Mehmet Asim Bilen, Jorge A. Garcia, Guru Sonpavde, Alexandra Drakaki, Pedro C. Barata, Gregory R. Pond, Jae-Lyun Lee, Ravindran Kanesvaran
Publikováno v:
Clinical Genitourinary Cancer. 19:425-433
PD1/L1 inhibitors are approved by FDA as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the ou
Publikováno v:
Hematol Oncol Clin North Am
At diagnosis, more than 70% of bladder cancers (BCs) are at the non-muscle-invasive bladder cancer (NMIBC) stages, which are usually treated with transurethral resection followed by intravesical instillation. For the remaining advanced cancers, syste
Autor:
Sumati Gupta, Theodore Stewart Gourdin, Aaron Hardin, Petros Grivas, Lesli A. Kiedrowski, Roby Antony Thomas, Nicholas J. Vogelzang, Guru Sonpavde, Kimberly M. Hamann, Bishoy Faltas
Publikováno v:
Bladder Cancer. 7:143-148
Detecting genomic alterations (GAs) in advanced urothelial carcinoma (aUC) can expand treatment options by identifying candidates for targeted therapies. Erdafitinib is FDA-approved for patients with platinum-refractory aUC with activating mutation o
Autor:
Devika Das, Terry Hyslop, Steven R. Patierno, Guru Sonpavde, Bonnie LaCroix, Tian Zhang, Brendon M. Patierno, Julia Rasmussen, Andrew J. Armstrong, A. Oliver Sartor, Patrick Healy, Kouros Owzar, James D. Bearden, Jennifer A. Freedman, Michael Moses Goodman, Kellie Shobe, Matthew I. Milowsky, Mark D. Fleming, Megan Ann McNamara, Michael R. Harrison, Julie Kephart, William R. Berry, Rhonda Wilder, Monika Anand, Carol Winters, Rick A. Kittles, Rhonda L. Bitting, Dadong Zhang, Colleen Riggan, Daniel J. George, Alexander B. Sibley, Elisabeth I. Heath, Susan Halabi
Publikováno v:
Cancer
BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus pre
Autor:
Daniel P. Petrylak, Guru Sonpavde, Yohann Loriot, Mary Campbell, Chunzhang Wu, Jonathan E. Rosenberg, Ignacio Duran, Nobuaki Matsubara, Thomas Powles, Maria Matsangou, Jae-Lyun Lee, Daniel Castellano, Christof Vulsteke
Publikováno v:
The New England journal of medicine
Background Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment. Methods We conducted a globa
Autor:
Aristotelis Bamias, Vadim S. Koshkin, Victor Sacristan Santos, Matthew D. Galsky, Ana Fröbe, Joseph J. Park, David J. Pinato, Pedro Isaacsson Velho, Christopher J. Hoimes, Pavlos Msaouel, Jayanshu Jain, Daniel Castellano, Leonidas Nikolaos Diamantopoulos, Benjamin A. Gartrell, Neeraj Agarwal, Abhishek Tripathi, Ali Raza Khaki, Rafael Morales-Barrera, Ajjai Alva, Stepan M. Esagian, Lucia Carril-Ajuria, Jure Murgic, Tyler F. Stewart, Sandy T. Liu, Evan Shreck, Monika Joshi, Noah M. Hahn, Pedro C. Barata, Mehmet Asim Bilen, Lucia Alonso Buznego, Marcus Marie Moses, Ivan de Kouchkovsky, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Petros Grivas, Evan Y. Yu, Alejo Rodriguez-Vida, Ignacio Duran, Alexander Sankin, Mark P. Lythgoe, Guru Sonpavde, Rana R. McKay, Michael Edward Devitt
Publikováno v:
BJU International. 128:196-205
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and methods: We perfo
Autor:
Lorine Häuser, Karl H. Tully, Quoc-Dien Trinh, Matthew Mossanen, Guru Sonpavde, Adam S. Kibel, Florian Roghmann, Joachim Noldus, Xi Chen
Publikováno v:
Clinical Genitourinary Cancer. 18:e651-e659
The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic
Publikováno v:
Archives of Pathology & Laboratory Medicine. 145:1000-1008
Context.— Plasmacytoid urothelial carcinoma (PC-UC) is an aggressive variant of urothelial carcinoma (UC), characterized by loss of E-cadherin (E-Cad)–mediated intercellular adhesion. Loss of E-Cad by immunohistochemistry can help diagnose PC-UC;
Autor:
Amishi Yogesh Shah, Arlene O. Siefker-Radtke, Aradhana M. Venkatesan, Subrina Farah, Glenn J. Bubley, Mehmet Asim Bilen, Wanling Xie, Matthew T. Campbell, Guru Sonpavde, Kerry L. Kilbridge, Amir Mortazavi, Atish D. Choudhury, Toni K. Choueiri, Bradley Alexander McGregor, Andrew Schmidt, Rana R. McKay
Publikováno v:
Cancer. 127:840-849
Background In this multicenter, single-arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder and upper tract carcinoma of variant histology (BUT
Autor:
Arwa A. Alzaghal, Guru Sonpavde, Francesco Alessandrino, Atul B. Shinagare, Amin Nassar, Arvind Ravi, Rahul Gujrathi, Bradley Alexander McGregor
Publikováno v:
European Urology Oncology. 3:680-686
Reliable biomarkers to predict the response of metastatic urothelial cancer (mUC) to programmed death-1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors are being investigated. Texture analysis represents tumor heterogeneity and may serve as a p